Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TTVBO-1MT: sourced facts only. name: "Mechanistic studies demonstrated that TTVBO-1MT mediated photoimmunotherapy through dual mechanisms involving autophagy induction and IDO1 inhibition." [PMID:40992172]; target: "Mechanistic studies demonstrated that TTVBO-1MT mediated photoimmunotherapy through dual mechanisms involving autophagy induction and IDO1 inhibition." [PMID:40992172]; developer: "Guangxi Key Laboratory of Drug Discovery and Optimization, Guangxi Engineering Research Center for Pharmaceutical Molecular Screening and Druggability Evaluation, Key Laboratory of Medical and Translational Medicine, School of Pharmacy, Guilin Medical University, Guilin, 541199, Guangxi, China." [PMID:40992172]; stage: "Comprehensive in vitro and in vivo evaluations using a model of triple-negative breast cancer revealed that TTVBO-1MT exhibited potent antitumor activity." [PMID:40992172]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TTVBO-1MT.